Ibrexafungerp (SCY-078, MK-3118)

Drupal spam blocked by CleanTalk.
Title Content type
Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI) (click for details)
Study to Evaluate the Safety and Efficacy of the Combination Therapy of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA) (click for details)
Ibrexafungerp Overview (click for details)
Clone of Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. (click for details)
Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates. (click for details)
Latest information on SCY-078 (MK-3118; enfumafungin) from Scynexis (click for details)
Discovery of Plant Sterol-Derived Gamma-Secretase Modulators by Molecular Editing of a Triterpenoid Glycoside (click for details)
A prospective, phase 2, multicentre, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vsstandard-of-care following initial intravenous echinocandin therapy in the treatment of.. (click for details)
Evaluation of the antifungal activity of SCY-078 in combination with other antifungals against Aspergillus strains (click for details)
A prospective, phase 2, multicentre, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vsstandard-of-care following initial intravenous echinocandin therapy in the treatment of.. (click for details)

Pages

Subscribe to Ibrexafungerp (SCY-078, MK-3118)